Biosystems unit eyes Rs 200 cr reagents production in 5 yrs

Tags: News
Biosystems Diagnostics, a joint venture between Chennai-based Trivitron Healthcare and Spanish company BioSystems hopes to produce reagents worth Rs 200 crore in the next three to five years. The JV opened its manufacturing facility at Trivitron Medical Technology Park in Chennai on Monday.

BioSystems is one of the leading manufacturers of clinical chemistry reagents and instruments, immunofluorescence reagents and instruments as well as immunoturbidimetry reagents for over three decades.

The facility has a built-up area of 45,000 sq ft and has a capacity of one lakh litres of reagents per year. The JV has invested $10 million in the facility.

“This plant would be incorporating all contemporary technologies and comply with European Standards for its operations and would be at par with the global standards in every way. The plant design is scalable to double the capacity in future. This facility will produce reagent worth over Rs 200 crore during next three to five years and it would not only cater to the domestic market but also supply to the other overseas markets.”

The Indian market for diagnostic reagents is highly dependent on imports. Almost 80 per cent of the products are brought into the country from the developed world, mainly US and Europe. Apart from catering to the domestic market the company will also look at exporting the products to emerging markets in Asia, Africa, Latin America and West Asia.

“Our association with Trivitron will successfully help the two leading companies to leverage its respective strengths in marketing and manufacturing,” said Antonio Elduque, CEO, Biosystems.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Signalling good times, current account deficit is likely to grow from here on

    The current account deficit (CAD) numbers for April-June quarter declined sharply to 1.7 per cent of GDP.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Disruptive innovation in education

The past two weeks had a fair share of interesting ...

Rajgopal Nidamboor

Regain the spirit of focused power

For aeons, the human race has been experimenting with a ...

Gautam Gupta

Manufacturing must keep workers’ welfare in mind

It may be early days yet, but the labour reforms ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture